Tech Company Financing Transactions

Avaxia Biologics Funding Round

Avaxia Biologics, based in Lexington, secured $2.9 million from private investors.

Transaction Overview

Company Name
Announced On
12/23/2013
Transaction Type
Debt
Amount
$2,872,388
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for solicitation details, if applicable.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
128 Spring St. 620
Lexington, MA 02421
USA
Email Address
Overview
Avaxia Biologics develops orally-delivered antibody therapeutics using a proprietary antibody platform.
Profile
Avaxia Biologics LinkedIn Company Profile
Social Media
Avaxia Biologics Company Twitter Account
Company News
Avaxia Biologics News
Facebook
Avaxia Biologics on Facebook
YouTube
Avaxia Biologics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Barbara Fox
  Barbara Fox LinkedIn Profile  Barbara Fox Twitter Account  Barbara Fox News  Barbara Fox on Facebook
Chief Financial Officer
David Neafus
  David Neafus LinkedIn Profile  David Neafus Twitter Account  David Neafus News  David Neafus on Facebook
VP - Operations
Neil Schauer
  Neil Schauer LinkedIn Profile  Neil Schauer Twitter Account  Neil Schauer News  Neil Schauer on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/23/2013: Aviary venture capital transaction
Next: 12/23/2013: GreenLight Biosciences venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We record every notable VC transaction. All VC database entries on this site are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary